Navigation Links
Dyadic International To Speak At Advanced Biofuels Leadership Conference Panel Discussion
Date:4/10/2013

JUPITER, Fla., April 10, 2013 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical and industrial enzyme industries, announced today that its President and CEO, Mark Emalfarb , will speak at the Advanced Biofuels Leadership Conference in Washington, DC, during its conference session: Hot Technologies & Products, at 2:30 p.m. EDT on April 17, 2013.

(Logo: http://photos.prnewswire.com/prnh/20110621/CL06708LOGO)

The Advanced Biofuels Leadership Conference has become one of the largest gatherings of CEOs, senior executives, strategic partners, financiers, equity analysts, policymakers and industry suppliers in the Advanced Biofuels & Renewable Chemicals and Biomaterials industries in North America. The conference brings these leaders together to showcase leading companies, technologies and business strategies, and to discuss crucial technologies, partnership, financial strategies, and energy, agricultural, tax and trade policy issues, that together are charting the future of the Biofuels & Renewable Chemicals and Biomaterials industries in the US and Internationally.

About Dyadic

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical and industrial enzyme industries. Please visit Dyadic's website at www.dyadic.com.

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.


'/>"/>
SOURCE Dyadic International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Dyadic International To Present At World Biofuels Markets
2. Dyadic International To Announce Year-End 2012 Financial Results And Host Conference Call On Thursday, March 7, 2013
3. Dyadic International Upgraded By OTC Markets To "Current Information" Tier
4. 12th U.S. Patent Issued To Dyadic International
5. Dyadic International Reports 2012 Third Quarter Financial Results
6. Dyadic Netherlands To Develop Baking Enzymes For EU-Funded Research Project
7. Dyadic International to Announce Second Quarter 2012 Financial Results and Host Conference Call on Monday, August 13, 2012
8. Dyadic Demonstrates Industry-leading Biofuels Enzyme Performance
9. Dyadic International To Release First Quarter 2012 Financial Results And Host Conference Call
10. Dyadic International Launches FibreZyme® G5000 High Performance Powder Pulp and Paper Enzyme in Booth #1065 at Tissue World Americas Conference
11. Dyadic International Partners with Leading Provider of Nutritional Ingredient Solutions for Production of Food Enzymes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... ... February 17, 2017 , ... The BMT Tandem Meetings of ... International Blood & Marrow Transplant Research (CIBMTR) will take place Feb. 22-26, 2017 ... combined scientific sessions offer investigators, clinicians, laboratory technicians, clinical research professionals, nurses, pharmacists, ...
(Date:2/17/2017)... , Feb. 17, 2017  BioGenex, a global ... development of a novel system for quantitative immunohistochemistry ... the University of Rochester (NY, USA) and Konica-Minolta ... new system is able to accurately quantify the ... (Human epidermal growth factor receptor-2) in clinical samples. ...
(Date:2/16/2017)... ... ... EIT Digital has launched work to develop a new Smart ... about to get under way for the framework, which is designed to reduce the ... expected to be transferred eventually to other industries that also require efficient IoT and ...
(Date:2/16/2017)... Feb. 16, 2017  MDNA Life Sciences Inc. ... of liquid biopsy tests based on the mitochondrial ... exclusive license agreement with its first international commercial ... biopsy test for prostate cancer, the Prostate Mitomic ... . This is the first overseas appointment for ...
Breaking Biology Technology:
(Date:2/8/2017)... 2017 The biometrics market has reached ... of organizations, desires to better authenticate or identify ... and challenge questions), biometrics is quickly working its ... market is driven by use cases, though there ... enterprise uses cases, with consumer-facing use cases encompassing ...
(Date:2/7/2017)... Feb. 7, 2017   MedNet Solutions , an ... spectrum of clinical research, is pleased to announce that ... its innovative, highly flexible and award winning eClinical solution, ... iMedNet is a proven Software-as-a-Service (SaaS) clinical ... Capture (EDC), but also delivers an entire suite of ...
(Date:2/7/2017)... York , February 7, 2017 ... ID Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or the ... and electronic transaction processing services, is pleased to announce ... the Company. Effective January 31, 2017, ... Board of Directors, CEO and President.  An experienced payment ...
Breaking Biology News(10 mins):